Abstract
Aminoglycoside antibiotics represent the first class of successful drugs in the treatment of tuberculosis; however, mycobacteria and other bacterial species possess several drug resistance mechanisms to inactivate these natural products. In the past 15 years, a variety of amphiphilic aminoglycosides have been shown to have improved activity against infectious microorganisms and to subvert resistance mechanisms. Here, we report on four novel synthetic compounds derived from two existing potent antitubercular compounds and describe their activity against both Mycobacterium tuberculosis and Staphylococcus aureus. It was found that a decanesulfonylacetamide-based conjugate of amikacin displayed promising preliminary antitubercular activities, warranting further investigation to assess the therapeutic potential of these unique antimicrobials.
Reference33 articles.
1. BB-K8, a new semisynthetic aminoglycoside antibiotic.;J Antibiot,1972
2. Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity.;J Med Chem,2010
3. Farr DC, Grice ID, Houston TA. Amphiphilic analogues of aminoglycosides as antitubercular and antimicrobial agents. In: Alves R, editor. . New York, NY, USA: Nova; 2016. pp. 1–52.
4. Surprising alteration of antibacterial activity of 5′′-modified neomycin against resistant bacteria.;J Med Chem,2008
5. Amphiphilic aminoglycosides as medicinal agents.;Int J Mol Sci,2020